Last reviewed · How we verify

NCT06295172

A Study Comparing Lafullen15 and Lafullen for Temporary Nasolabial Fold Improvement

Not yet recruiting NA Last updated 14 May 2024
What this trial tests

NA trial testing Lafullen15 in Nasolabial Folds in 73 participants. Not yet recruiting.

Timeline
27 May 2024
Primary endpoint
30 September 2025
30 April 2026

Quick facts

Lead sponsorSamyang Biopharmaceuticals Corporation
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment73
Start date27 May 2024
Primary completion30 September 2025
Estimated completion30 April 2026

Drugs / interventions tested

Conditions studied

Sponsor

Samyang Biopharmaceuticals Corporation — full company profile →

Who can join

Adults 19 to 70, any sex, with Nasolabial Folds. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this clinical trial is to verify the safety and efficacy of Lafullen15 in the temporary improvement of nasolabial Folds

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Samyang Biopharmaceuticals Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06295172.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing